PODD - インスレット (Insulet Corporation)

PODDのニュース

   Insulet Corporation Shares Close the Week 20.7% Lower - Weekly Wrap  2021/05/07 22:30:00 Kwhen Finance
Insulet Corporation (PODD) shares closed this week 20.7% lower than it did at the end of last week. The stock is currently down 8.4% year-to-date, up 8.8% over the past 12 months, and up 686.7% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 1.2%. Trading Activity Shares traded as high as $297.01 and as low as $232.20 this week.Shares closed 2e+1% below its 52-week high and 4e+1% above its 52-week low.Trading volume this week was 40.6% higher than the 10-day average and 155.2% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 296.6% The company's stock price performance over the past 12 months lags the peer average by -31.4% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 35451.2% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx  2021/04/29 12:15:49 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ: AXNX ) Boston Scientific Corporation (NYSE: BSX ) (reacted to first-quarter results) Celcuity Inc. (NASDAQ: CELC ) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Galectin Therapeutics Inc. (NASDAQ: GALT ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Integra LifeSciences Holdings Corporation (NASDAQ: IART ) (announced first-quarter results) Lantheus Holdings, Inc. (NASDAQ: LNTH ) MacroGenics, Inc. (NASDAQ: MGNX ) NuVasive, Inc. (NASDAQ: NUVA) PRA Health Sciences, Inc. (NASDAQ: PRAH ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Verastem, Inc. (NASDAQ: VSTM ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 28) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Decibel Therapeutics, Inc. (NASDAQ: DBTX ) IRadimed Corporation (NASDAQ: IRMD ) Lucira Health, Inc. (NASDAQ: LHDX ) Mesoblast Limited (NASDAQ: MESO ) Protara Therapeutics, Inc. (NASDAQ: TARA ) PTC Therapeutics, Inc. (NASDAQ: PTCT ) Stocks In Focus Adverum Shares Sink On Serious Adverse Event Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) announced a suspected unexpected serious adverse reaction of hypotony, which is clinically relevant decrease in ocular pressure, in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema.
   Insulet Corp’s Omnipod 5 Shows Improved Outcomes In Type 1 Diabetes; Street Sees 10% Upside  2021/03/22 12:24:40 TipRanks
Insulet Corporation reported positive results from its first trial of Omnipod 5, an automated insulin delivery system for the treatment of Type 1 diabetes. Insulet’s (…
   Insulet’s Omnipod® 5 Automated Insulin Delivery System Improves Clinical Outcomes in Type 1 Diabetes  2021/03/20 15:45:00 Business Wire
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced positive results from the first pivotal trial for the Omnipod® 5 Automated Insulin Delivery System. Omnipod 5, the world’s first tubeless, wearable system that continuously adapts insulin delivery based on glucose levels and trends, significantly improved time in range and reduced HbA1c in children,
   Europe Continuous Glucose Monitoring Systems Market 2021 Global Industry Analysis by Top Key Players,Types, Key Regions Demand and Future Growth till 2027 | Echo Therapeutics Inc., Insulet Corporation, Johnson & Johnson, Medtronic plc, Senseonics Holding  2021/03/17 13:37:26 OpenPR
Europe Continuous Glucose Monitoring Systems Market Report, published by Allied Market Research, forecasts that the market was valued $58 million in 2015, and is expected to reach $792 million by 2027, supported by a CAGR of 44.9% during the forecast
   Insulet Reports Full Year 2020 Revenue Increase of 23% and Fourth Quarter 2020 Revenue Increase of 18% Year-Over-Year  2021/02/23 21:01:00 Business Wire
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months and full year ended December 31, 2020. Full Year Financial Highlights: Full Year 2020 revenue of $904.4 million, up 22.5%, or 21.9% in constant currency1, compared to $738.2 million in the prior year, exceeds guidance of 20% to 21% on a
   Europe Continuous Glucose Monitoring Systems Market 2021 Global Industry Analysis by Top Key Players,Types, Key Regions Demand and Future Growth till 2027 | Echo Therapeutics Inc., Insulet Corporation, Johnson & Johnson, Medtronic plc, Senseonics Holding  2021/03/17 13:37:26 OpenPR
Europe Continuous Glucose Monitoring Systems Market Report, published by Allied Market Research, forecasts that the market was valued $58 million in 2015, and is expected to reach $792 million by 2027, supported by a CAGR of 44.9% during the forecast
   Insulet Reports Full Year 2020 Revenue Increase of 23% and Fourth Quarter 2020 Revenue Increase of 18% Year-Over-Year  2021/02/23 21:01:00 Business Wire
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months and full year ended December 31, 2020. Full Year Financial Highlights: Full Year 2020 revenue of $904.4 million, up 22.5%, or 21.9% in constant currency1, compared to $738.2 million in the prior year, exceeds guidance of 20% to 21% on a
   Europe Wearable Injectors Market Set to Expand by 2020-2027 Focusing on Key Players BD, CeQur SA, Debiotech S.A, Insulet Corporation, Gerresheimer AG, Amgen, Inc  2021/02/23 09:18:33 OpenPR
The Europe wearable injectors market is expected to reach US$ 3586.82 million in 2027 from US$ 1539.88 million in 2019. The market is estimated to grow with a CAGR of 11.3 % from 2020 to 2027. Get Sample Copy of this
   Tubeless Insulin Pump Market With Leading Players like Insulet Corporation, Johnson and Johnson, Medtrum Technologies Inc., Roche Holding AG, Cellnovo Group SA, Spring Health Solution Ltd., Debiotech, CeQur SA Valeritas, Abbott Diabetes Care  2021/02/23 08:20:30 OpenPR
An off-the-shelf report on Tubeless Insulin Pump Market which has been compiled after an in-depth analysis of the market trends prevailing across five geographies (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). Various segments of the market such
   Insulet Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/02/22 12:25:00 Stock Market Daily
Insulet announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

calendar